Related Experiment Videos
Membrane-anchored peptide inhibits human immunodeficiency virus entry
M Hildinger1, M T Dittmar, P Schult-Dietrich
1Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie an der Universität Hamburg, Germany.
Journal of Virology
|February 27, 2001
Summary
Membrane-anchored T20 peptides effectively block HIV-1 entry into T-helper cells. This novel approach significantly inhibits viral replication, offering a promising strategy against HIV-1 infection regardless of coreceptor usage.
Area of Science:
- Virology
- Molecular Biology
- Immunology
Background:
- Human immunodeficiency virus (HIV) entry is mediated by the gp41 envelope glycoprotein.
- Peptides targeting gp41 heptad repeats, like T20, are known HIV entry inhibitors.
- Cellular strategies for enhancing antiviral peptide efficacy are under investigation.
Purpose of the Study:
- To investigate the efficacy of cell surface-anchored T20 peptides in inhibiting HIV-1 replication.
- To determine if membrane-anchored T20 inhibition is dependent on HIV coreceptor usage.
Main Methods:
- Retrovirus vector-mediated transduction of a T-helper cell line to express membrane-anchored T20.
- Quantification of HIV-1 replication in engineered T-helper cells.
- Assessment of inhibition across different HIV-1 coreceptor usage patterns.
Main Results:
- HIV-1 replication was inhibited over 100-fold in cells expressing membrane-anchored T20.
- The observed inhibition was independent of the coreceptor usage (CCR5 or CXCR4) of the HIV-1 strains.
- Cell surface expression of T20 demonstrated potent antiviral activity.
Conclusions:
- Cell surface-anchored T20 is a highly effective inhibitor of HIV-1 entry and replication.
- This strategy provides broad-spectrum inhibition against HIV-1, irrespective of coreceptor tropism.
- Membrane-anchored peptides represent a promising therapeutic approach for HIV-1 prevention and treatment.